This company has been acquired
Semler Scientific Toekomstige groei
Future criteriumcontroles 0/6
De omzet en winst van Semler Scientific zullen naar verwachting dalen met respectievelijk 5.7% en 187.8% per jaar, terwijl de winst per aandeel naar verwachting zal dalen met 195.4% per jaar.
Belangrijke informatie
-187.8%
Groei van de winst
-195.44%
Groei van de winst per aandeel
| Medical Equipment winstgroei | 16.3% |
| Inkomstengroei | -5.7% |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 16 Jan 2026 |
Recente toekomstige groei-updates
Recent updates
SMLR: All Stock Strive Deal Will Unlock Bitcoin Treasury Upside
Analysts have reaffirmed their fair value estimate for Semler Scientific at US$86.00, highlighting adjusted assumptions around the discount rate, revenue trends and profit margin, along with a lower but still very large future P/E expectation as the key drivers behind holding the target steady. What's in the News Strive, Inc.
SMLR: Future Profits And January Meeting Will Support Bullish Thesis
Analysts have reduced their price target on Semler Scientific from US$60.00 to US$51.00, citing softer revenue growth assumptions, a higher discount rate, and a very large future P/E multiple, even as projected profit margins edge slightly higher. What's in the News Semler Scientific has scheduled a special or extraordinary shareholders meeting for January 13, 2026, giving investors a date to watch for company level decisions or approvals that require shareholder input (Key Developments).SMLR: All Stock Acquisition Will Unlock Bitcoin Treasury Upside
Analysts have reduced their price target on Semler Scientific to $86 from $101, citing lower revenue and margin forecasts, as well as uncertainty and opportunity created by the recent all stock acquisition agreement and legal settlement. Analyst Commentary Bullish analysts acknowledge the reduced price targets but continue to frame the all stock acquisition and legal settlement as catalysts that could unlock value for Semler Scientific over the medium term.
SMLR: Shares Will Rise As All Stock Acquisition Drives Bitcoin Treasury Consolidation
Analysts have trimmed their average price target for Semler Scientific by about $15 to roughly $83 per share, citing reduced revenue expectations following updated management guidance and the implications of the recent DOJ settlement. They continue to view the stock as an attractive opportunity in light of the pending all stock acquisition by Strive and consolidation prospects in the corporate bitcoin treasury space.SMLR: Shares Will Reflect Upside As $1.4 Billion Acquisition Advances
Analysts have lowered their fair value estimate for Semler Scientific by approximately $10. This change is due to reduced revenue growth projections and updated guidance in light of recent acquisition and settlement developments.Cardiac And Digital Health Expansion Will Encounter Bitcoin Risks
Analysts have lowered their price target for Semler Scientific from $85.33 to $75.33, citing reduced revenue forecasts following cautious management guidance, weighing of recent legal settlements, and uncertainty around the company’s pivot to a bitcoin treasury strategy despite some bullish views on its potential long-term re-rating. Analyst Commentary Bullish analysts see the acquisition by Strive (ASST) as triggering potential consolidation in the corporate bitcoin treasury sector, presenting a timely opportunity despite market uncertainty around the transaction’s longer-term implications.Is Semler Scientific (NASDAQ:SMLR) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Cardiac And Digital Health Expansion Will Encounter Bitcoin Risks
Diversification into cardiac disease markets and value-based care tools positions the company for higher recurring revenues and improved long-term margins.Semler Scientific, Inc.'s (NASDAQ:SMLR) 26% Share Price Surge Not Quite Adding Up
Semler Scientific, Inc. ( NASDAQ:SMLR ) shares have had a really impressive month, gaining 26% after a shaky period...Semler Scientific: Not The Ideal Bitcoin Treasury Company
Summary Semler Scientific's pivot to a Bitcoin treasury strategy has been successful. However, competition in the Bitcoin Treasury company space is heating up, including many well funded competitors. Declining revenues and free cash flow in its healthcare business are concerning, and Bitcoin is materially outperforming the Company year to date. Read the full article on Seeking AlphaSemler Scientific, Inc.'s (NASDAQ:SMLR) 32% Price Boost Is Out Of Tune With Revenues
Semler Scientific, Inc. ( NASDAQ:SMLR ) shareholders are no doubt pleased to see that the share price has bounced 32...Here's Why We Think Semler Scientific (NASDAQ:SMLR) Might Deserve Your Attention Today
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Semler Scientific's (NASDAQ:SMLR) Profits May Not Reveal Underlying Issues
The recent earnings posted by Semler Scientific, Inc. ( NASDAQ:SMLR ) were solid, but the stock didn't move as much as...Semler Scientific, Inc. (NASDAQ:SMLR) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Unfortunately for some shareholders, the Semler Scientific, Inc. ( NASDAQ:SMLR ) share price has dived 25% in the last...Semler Scientific, Inc. (NASDAQ:SMLR) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely
Semler Scientific, Inc. ( NASDAQ:SMLR ) shares have retraced a considerable 26% in the last month, reversing a fair...Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 34 | -3 | -3 | -3 | 2 |
| 12/31/2025 | 34 | 5 | -1 | -1 | 2 |
| 9/30/2025 | 37 | 48 | -27 | -27 | N/A |
| 6/30/2025 | 43 | 37 | 12 | 12 | N/A |
| 3/31/2025 | 49 | -30 | 17 | 17 | N/A |
| 12/31/2024 | 56 | 41 | 24 | 24 | N/A |
| 9/30/2024 | 59 | 16 | 22 | 21 | N/A |
| 6/30/2024 | 62 | 16 | 20 | 20 | N/A |
| 3/31/2024 | 66 | 22 | 26 | 26 | N/A |
| 12/31/2023 | 68 | 21 | 21 | 21 | N/A |
| 9/30/2023 | 67 | 20 | 17 | 19 | N/A |
| 6/30/2023 | 65 | 18 | 20 | 22 | N/A |
| 3/31/2023 | 61 | 16 | 14 | 17 | N/A |
| 12/31/2022 | 57 | 14 | 15 | 17 | N/A |
| 9/30/2022 | 54 | 13 | 16 | 17 | N/A |
| 6/30/2022 | 54 | 13 | 16 | 17 | N/A |
| 3/31/2022 | 54 | 16 | 12 | 13 | N/A |
| 12/31/2021 | 53 | 17 | 15 | 16 | N/A |
| 9/30/2021 | 54 | 21 | 19 | 20 | N/A |
| 6/30/2021 | 50 | 22 | 15 | 16 | N/A |
| 3/31/2021 | 42 | 16 | 15 | 16 | N/A |
| 12/31/2020 | 39 | 14 | 14 | 15 | N/A |
| 9/30/2020 | 36 | 11 | 12 | 13 | N/A |
| 6/30/2020 | 34 | 14 | 13 | 14 | N/A |
| 3/31/2020 | 35 | 16 | 13 | 15 | N/A |
| 12/31/2019 | 33 | 15 | 11 | 13 | N/A |
| 9/30/2019 | 30 | 14 | 10 | 11 | N/A |
| 6/30/2019 | 26 | 7 | N/A | 8 | N/A |
| 3/31/2019 | 24 | 6 | N/A | 7 | N/A |
| 12/31/2018 | 21 | 5 | N/A | 5 | N/A |
| 9/30/2018 | 20 | 4 | N/A | 3 | N/A |
| 6/30/2018 | 18 | 2 | N/A | 2 | N/A |
| 3/31/2018 | 15 | 0 | N/A | 1 | N/A |
| 12/31/2017 | 12 | -2 | N/A | 1 | N/A |
| 9/30/2017 | 11 | -2 | N/A | 0 | N/A |
| 6/30/2017 | 9 | -2 | N/A | 0 | N/A |
| 3/31/2017 | 8 | -2 | N/A | -1 | N/A |
| 12/31/2016 | 7 | -3 | N/A | -2 | N/A |
| 9/30/2016 | 8 | -7 | N/A | -4 | N/A |
| 6/30/2016 | 7 | -8 | N/A | -3 | N/A |
| 3/31/2016 | 7 | -8 | N/A | -4 | N/A |
| 12/31/2015 | 7 | -9 | N/A | -4 | N/A |
| 9/30/2015 | 5 | -5 | N/A | -4 | N/A |
| 6/30/2015 | 4 | -5 | N/A | -4 | N/A |
| 3/31/2015 | 4 | -5 | N/A | -4 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De winst van SMLR zal naar verwachting de komende 3 jaar dalen ( -187.8% per jaar).
Winst versus markt: De winst van SMLR zal naar verwachting de komende 3 jaar dalen ( -187.8% per jaar).
Hoge groeiwinsten: De winst van SMLR zal naar verwachting de komende 3 jaar dalen.
Omzet versus markt: De omzet van SMLR zal naar verwachting de komende 3 jaar dalen ( -5.7% per jaar).
Hoge groei-inkomsten: De omzet van SMLR zal naar verwachting de komende 3 jaar dalen ( -5.7% per jaar).
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van SMLR naar verwachting over 3 jaar hoog zal zijn
Ontdek groeibedrijven
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/01/20 17:10 |
| Aandelenkoers aan het einde van de dag | 2026/01/15 00:00 |
| Inkomsten | 2025/09/30 |
| Jaarlijkse inkomsten | 2024/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Semler Scientific, Inc. wordt gevolgd door 3 analisten. 2 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Mark Palmer | Benchmark Company |
| Marc Wiesenberger | B. Riley Securities, Inc. |
| Brett Knoblauch | Cantor Fitzgerald & Co. |